市場調査レポート

インドの医薬品市場

The Pharmaceutical Market: India

発行 Espicom Business Intelligence 商品コード 242157
出版日 ページ情報 英文 117 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
インドの医薬品市場 The Pharmaceutical Market: India
出版日: 2013年01月31日 ページ情報: 英文 117 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、インドの医薬品市場について、市場全体の動向と法規制、 医薬品流通チャネルなどを分析し、OTC医薬品、ジェネリック医薬品、 バイオ医薬品・バイオシミラーなどのセグメント別の動向、市場の機会と課題などを併せ、 概略下記の構成でお届けいたします。

目次

エグゼクティブサマリー

  • スナップショット: Espicom の戦略的分析
  • スナップショット: 主要データ予測

マクロ環境

  • 政治環境
  • 経済環境
  • 法環境
  • 人口統計

疫学

  • 病気の負荷
  • 羅漢率

ヘルスケア - 保健統計付

  • 組織・機構
  • 医療費
  • インフラストラクチャー
  • 労働力

規制関連情報

  • 国内当局
  • 規制の進展状況
  • 市場登録
  • プロモーション

価格決定

流通チャネル

市場分析

  • 規模
  • 製品開発
  • 製造
  • 貿易

競合状況

  • 事業者団体
  • 見本市
  • 企業情報
  • 競合戦略

生物製剤/バイオシミラー

  • 競合状況
  • 競合戦略

結び: 機会と課題

  • Espicom の戦略的分析
  • レーダー解析およびSWOT分析

関係各機関・組織一覧

  • 政府組織
  • 製薬会社
  • 事業者団体

図表


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Summary

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Description

THE PHARMACEUTICAL MARKET: INDIA - REVIEW

The Indian pharmaceutical market is highly competitive and remains dominated by low-priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region.

India's biopharmaceutical sector is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market. Growth drivers include education and increased awareness of disease prevention, increases in disposable income and government participation in immunisation programmes. Continued growth is also expected in the diagnostic and therapeutic segments, including cancer and diabetes. India is already known as the diabetes capital of the world and the number of diabetes patients in India is expected to grow to 70 million by 2025. Cancer therapies are also lucrative for many Indian companies due to high unmet need, increased awareness and the comparative affordability of domestically produced drugs.

The Indian pharmaceutical industry is responsible for around 10% of world pharmaceutical production. Over the last few years, a number of Indian pharmaceutical companies have been targeted for foreign acquisition. Concerns have been raised that this trend could adversely affect generic drug prices in India. The Ministry of Health wants safeguards built into the Foreign Direct Investment process amid fears that continued foreign acquisitions will adversely affect the domestic industry and push prices up, thereby potentially undermining the government's efforts to make generic drugs affordable. This could lead to essential medicines becoming more expensive and adversely affecting public health programmes.

The need to maintain low prices for essential medicines has been addressed in the government's draft National Pharmaceutical Pricing Policy (NPPP), released in 2011. The proposed NPPP focuses on the National List of Essential Medicines (NLEM), which is periodically revised. The headline major change is a move from the principle of cost-based pricing to a market-based pricing model. The Department of Pharmaceuticals argues that market-based pricing would result in more transparent and fair pricing, as well as increasing competition in the marketplace. Price regulation will encompass all drugs listed in the NLEM, as well as formulations containing combinations of drugs listed in the NLEM; this will include combinations comprising listed drugs and unlisted drugs. If the NPPP is implemented, around 60% of the drugs currently available in India will come under price control.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Table of Contents

BMI Industry View

SWOT

  • Political
  • Economic
  • Business Environment

Industry Forecast

  • Overall Market Forecast
  • Table: Pharmaceutical Sales, 2009-2017
  • Table: Total Healthcare Expenditure, 2009-2017
  • Table: Governmental Healthcare Expenditure, 2009-2017
  • Table: Private Healthcare Expenditure, 2009-2017
  • Economic Analysis
  • Prescription Drug/Patented
  • Table: Prescription Drug Sales, 2009-2017
  • Table: Patented Drug Sales, 2009-2017
  • Patented Drug Market Forecast
  • Table: Patented Drug Sales, 2009-2017
  • Generics
  • Table: Table: Generic Drug Sales, 2009-2017
  • OTC
  • Table: Table: OTC Medicine Sales, 2009-2017
  • Export/Import
  • Medical Devices Trade
  • Other Healthcare

Industry Risk Reward Ratings

  • Table: Table: Asia Pacific Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113
  • Rewards
  • Risks

Market Overview

Industry Trends And Developments

  • Epidemiology
  • Healthcare Sector
  • Healthcare Funding
  • Healthcare Insurance
  • Research & Development
  • Table: R&D EXPENDITURE IN TOP 20 INDIAN PHARMACEUTICAL FIRMS (BY MARKET CAPITALISATION)
  • Clinical Trials
  • Foreign Direct Investment
  • Biosimilars
  • Table: LIST OF SELECTED BIOSIMILARS DEVELOPED BY INDIAN PHARMACEUTICAL FIRMS
  • Traditional Medicines

Regulatory Development

  • Regulatory Environment
  • Table: Department Of Pharmaceuticals' Responsibilities
  • Pharmaceutical Advertising
  • Pharmacovigilance
  • Intellectual Property Regime
  • Table: History Of The Indian Patent System
  • Pricing Policy
  • Compulsory Licences

Competitive Landscape

  • Government Provision Of Pharmaceuticals
  • Key Pharmaceuticals And Healthcare Industry Developments 7
  • Production
  • Wholesale
  • Retail

Company Profile

  • Cipla
  • Ranbaxy
  • Dr. Reddy
  • Aurobindo
  • Pfizer
  • GSK
  • Novartis
  • Sanofi
  • Merck & Co

Demographic Forecast

  • Table: India's Population By Age Group, 1990-2020 ('000)
  • Table: India's Population By Age Group, 1990-2020 (% of total)
  • Table: India's Key Population Ratios, 1990-2020
  • Table: India's Rural And Urban Population, 1990-2020

Glossary

Methodology

  • Methodology
  • Risk/Reward Ratings Methodology
  • Ratings Overview
  • Table: Pharmaceutical Business Environment Indicators
  • Weighting
  • Sources
Back to Top